Entity

Time filter

Source Type

Mont-Saint-Aignan, France

The University of Rouen is a French university, in the Academy of Rouen. Wikipedia.


Patent
French Institute of Health, Medical Research, University of Rouen and Kagoshima University | Date: 2014-04-16

The present invention relates to antibodies which bind human ghrelin and their use in methods of treating or preventing reduced appetite. The invention further relates to diagnostic tools for determining whether an individual is likely to respond to a method of treating or preventing reduced appetite.


Coquerel G.,University of Rouen
Chemical Society Reviews | Year: 2014

The aim of the tutorial review is to show that any crystallization from solution is guided by stable or metastable equilibria and thus can be rationalized by using phase diagrams. Crystallization conducted by cooling, by evaporation and by anti-solvent addition is mainly considered. The driving force of crystallization is quantified and the occurrence of transient metastable states is logically explained by looking at the pathways of crystallization and the progressive segregation which might occur in a heterogeneous system. This journal is © the Partner Organisations 2014. Source


Patent
French Institute of Health, Medical Research, French National Center for Scientific Research, University of Rouen and University of Reims Champagne Ardenne | Date: 2015-10-21

The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.


New highly functionalizable Huprine derivatives of formula I: and


Patent
University of Rouen | Date: 2014-04-17

The present invention relates to methods and kits for testing the genotoxicity of an agent. In particular, the present invention provides a global assay for the measurement of genotoxic stress based on p53 target gene induction. In particular, the present invention relates to a method for testing the genotoxicity of an agent comprising the steps consisting of i) providing a population of test cells, ii) exposing the populations of test cells with the agent to be tested, iii) determining the expression level of at least one p53 target gene selected from the group consisting of ATF3, BBC3, CABYR, C10ORF10; EMX1; FHL2, GLS2; GRHL3; HES2; IGF-BP4; KIAA0284; PODXL1; RRAD; TP53I3, and XPC in the population of test cells exposed to the agent to be tested iv) comparing the expression level determined at step iii) with the expression level determined when the population of test cells was not exposed to the agent to be tested, and v) concluding that the agent is genotoxic when the expression level determined at step iii) is higher than the level determined when the population of test cells was not exposed to the agent to be tested.

Discover hidden collaborations